Exact Sciences Corporation (EXAS)

NASDAQ: EXAS · IEX Real-Time Price · USD
45.15
+2.91 (6.89%)
At close: Jun 24, 2022 4:00 PM
44.40
-0.75 (-1.66%)
After-hours: Jun 24, 2022 7:56 PM EDT
6.89%
Market Cap 7.94B
Revenue (ttm) 1.85B
Net Income (ttm) -745.40M
Shares Out 175.94M
EPS (ttm) -4.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,141,504
Open 42.51
Previous Close 42.24
Day's Range 42.09 - 45.18
52-Week Range 35.34 - 133.99
Beta 1.24
Analysts Buy
Price Target 98.46 (+118.1%)
Earnings Date Jul 27, 2022

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX... [Read more...]

Industry Biotechnology
Founded 1995
CEO Kevin Conroy
Employees 6,420
Stock Exchange NASDAQ
Ticker Symbol EXAS
Full Company Profile

Financial Performance

In 2021, Exact Sciences's revenue was $1.77 billion, an increase of 18.49% compared to the previous year's $1.49 billion. Losses were -$595.63 million, -27.68% less than in 2020.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is 98.46, which is an increase of 118.07% from the latest price.

Price Target
$98.46
(118.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

5 Health Care Stocks Cathie Wood Favors

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

Other symbols: BEAMCRSPNTLATDOC

5 Cathie Wood Stocks to Buy in June

Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on Investo...

Other symbols: IONSKTOSPATHTRMB

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations...

MADISON, Wis. , May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance too...

Exact Sciences to participate in June investor conferences

MADISON, Wis. , May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following confe...

Why Is Exact Sciences (EXAS) Down 22.5% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.

Exact Sciences to participate in May investor conference

MADISON, Wis. , May 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following confer...

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and ...

Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxP...

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up

Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ: EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% ...

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 7.14% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences Announces First Quarter 2022 Results

Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing revenue of $27M Total first quarter revenue, excluding COVID-19 test...

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.

Exact Sciences schedules first quarter 2022 earnings call

MADISON, Wis. , April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company plans to release its first quarter 2022 finan...

2 Top Biotech Stocks to Buy for the Long Haul

Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.

Other symbols: RGEN

Exact Sciences (EXAS) Down 4.3% Since Last Earnings Report: Can It Rebound?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Tesla, Coinbase, Exact Sciences And More: How Cathie Wood's Top 10 Bets Are Faring In 2022 So Far

Popular stockpicker Cathie Wood-led Ark Investment Management's top ten key bets — spread across clean energy, innovation, tech, healthcare, and space sectors that constitute nearly half of its investme...

Other symbols: COIN

Exact Sciences (EXAS) Gains But Lags Market: What You Should Know

Exact Sciences (EXAS) closed at $72.26 in the latest trading session, marking a +0.81% move from the prior day.

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

NEW YORK and MADISON, Wis., March 7, 2022 /PRNewswire/ -- Katie Couric, award winning journalist and colorectal cancer advocate who normalized talking about colon cancer more than two decades ago, today...

Exact Sciences to participate in March investor conferences

MADISON, Wis., Feb. 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following confe...

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-19 testing revenues, which dropped 52% to $...

Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?